TY - JOUR T1 - Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016 JF - The Journal of Rheumatology JO - J Rheumatol SP - 1522 LP - 1528 DO - 10.3899/jrheum.160904 VL - 44 IS - 10 AU - Ana-Maria Orbai AU - Maarten de Wit AU - Philip J. Mease AU - Kristina Callis Duffin AU - Musaab Elmamoun AU - William Tillett AU - Willemina Campbell AU - Oliver FitzGerald AU - Dafna D. Gladman AU - Niti Goel AU - Laure Gossec AU - Pil Hoejgaard AU - Ying Ying Leung AU - Chris Lindsay AU - Vibeke Strand AU - Désirée M. van der Heijde AU - Bev Shea AU - Robin Christensen AU - Laura Coates AU - Lihi Eder AU - Neil McHugh AU - Umut Kalyoncu AU - Ingrid Steinkoenig AU - Alexis Ogdie Y1 - 2017/10/01 UR - http://www.jrheum.org/content/44/10/1522.abstract N2 - Objective. To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS).Methods. At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants.Results. We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient’s global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda.Conclusion. The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set. ER -